Tianjin Medical University Second Hospital

This study tests whether the drug toripalimab can help prevent high-risk kidney cancer from returning after surgery to remove the kidney. About 100 adults will receive toripalimab by IV every three weeks for up to one year. Researchers will monitor them for cancer recurrence and …